Table 1 Baseline clinical features and renal outcomes in family history-positive and -negative subgroups of IgA nephropathy
Variables | Familial History of Renal Diseases | P value | |
|---|---|---|---|
Negative | Positive | ||
Number of Patients | n = 347 | n = 42 | |
Clinical backgorund at renal biopsy | |||
Age (yr) | 35 [15, 76] | 39 [19, 70] | 0.20 |
Age onset of hematuria and/or proteinuria (yr) | 28 [5, 75] | 26 [10, 66] | 0.99 |
Gender Male (n) | 171 (49.3) | 15 (35.7) | 0.10 |
Female (n) | 176 (50.7) | 27 (64.3) | |
eGFR (ml/min/1.73m2) | 74.00 [30.00, 153.00] | 69.50 [32.00, 115.20] | 0.048 |
History of Hypertension (n) | 247 (71.2) | 24 (57.1) | 0.08 |
History of Diabetes (n) | 17 (4.9) | 2 (4.8) | 1.00 |
Mean arterial pressure (mmHg) | 85 [55, 141] | 88 [67, 107] | 0.46 |
Urinalysis of RBC (per HPF) | 5 [1, 100] | 10 [1, 100] | 0.57 |
Urinary protein excretion per day (gram) | 0.55 [0.00, 20.86] | 0.47 [0.00, 5.05] | 0.67 |
Renal biopsy findings | |||
C3 deposition in mesangium | 1 [0, 3] | 1 [0, 3] | 0.34 |
C4 desposition in mesangium | 0 [0, 3] | 0 [0, 1] | 0.24 |
IgA deposition in mesangium | 2 [1, 3] | 2 [1, 3] | 0.70 |
IgG deposition along the capillary loops | 0 [0, 3] | 0 [0, 2] | 0.55 |
Oxford MEST-C Score | |||
M Score 1 (proportion, %) | 169 (48.7) | 21 (50.0) | 1.00 |
E Score 1 (proportion, %) | 34 (9.8) | 6 (14.3) | 0.42 |
S Score 1 (proportion, %) | 57 (16.4) | 5 (11.9) | 0.66 |
T Score (0–2) by 1 increase | 0.27 (0.50) | 0.31 (0.47) | 0.66 |
C score 1 to 0 (proportion, %) | 66 (19.0) | 6 (19.0) | 1.00 |
GBM thickness (nm) | 293.3 [131,422] | 294.0 [159,455] | 0.93 |
Number of patients with thin GBM(%) | 13 (3.7) | 2 (4.8) | 0.69 |
Renal Outcomes | |||
Age at last evaluation (yr) | 46.00 [18.00, 87.00] | 45.00 [24.00, 80.00] | 0.44 |
Observational peroid (yr) | 9.00 [2.00, 25.00] | 8.00 [2.00, 25.00] | 0.47 |
eGFR (ml/min/1.73 m2) | 66.00 [5.00, 160.50] | 54.00 [5.00, 106.50] | 0.02 |
Mean eGFR reduction (ml/min/1.73m2/year) | −0.88 [−24.00, 10.23] | −1.09 [−13.20, 5.25] | 0.35 |
More than 50% reduction of eGFR(proportion, %) | 41 (11.8) | 10 (23.8) | 0.048 |
CKD stage 5 (proportion, %) | 27 (7.8) | 8 (19.0) | 0.04 |
CKD stage 4 or 5 (proportion, %) | 42 (12.1) | 12 (28.6) | 0.01 |
Primary outcome (proportion, %) | 41 (11.8) | 10 (23.8) | 0.048 |
Therapy and intervension | |||
Administration of immunosupressant (proportion %) | 6 (1.7) | 1 (2.4) | 0.55 |
Adminstration of RAS inhibitors (%) | 218 (62.8) | 31 (73.8) | 0.18 |
Tonsillectomy plus steroid-pulse therapy (%) | 171 (49.3) | 25 (59.5) | 0.25 |
long-term oral prednisolone (%) | 35 (10.1) | 2 (4.8) | 0.40 |